Background
Familial Mediterranean fever (FMF) is an autoinflammatory disease caused by Mediterranean fever (
MEFV) gene mutations located on the short arm of chromosome 16 (16 pm 13.3) [
1,
2]. FMF is characterized by recurrent and self-limiting fever attacks in a short period accompanied by serositis manifestations including peritonitis and pleuritis, musculoskeletal manifestations including synovitis and myalgia, and skin manifestations including erysipelas-like skin lesions [
3‐
6]. A patient’s FMF can be classified as a typical or an atypical case based on clinical findings and genetic testing [
7‐
9]. According to the Tel Hashomer criteria, a typical case is characterized by fever attacks of ≥ 38.0 °C and lasting 12–72 h accompanied by pleuritis, nonlocalized peritonitis, and monoarthritis of the hip, knee, or ankle [
7], whereas an atypical case is characterized by fever attacks of < 38.0 °C, lasting only a short period (i.e., 6–12 h) or lasting a long period (72 h–7 days), abdominal pain without definitive peritonitis, localized peritonitis, or arthritis outside the typical sites (i.e., hip, knee, and ankle) [
7].
FMF is most prevalent in individuals in the Mediterranean and Middle Eastern regions, especially in Turks, Arabs, Armenians, and non-Ashkenazi Jews [
10,
11]. However, FMF cases have increasingly been reported in some countries outside these regions, such as Japan and the USA [
12]. In particular, Japanese FMF cases with
MEFV mutations were described for the first time in 2002 [
13], and there is accumulating evidence showing the characteristics of FMF in Japan [
9,
14‐
19]. The frequency of FMF cases with high-penetrance
MEFV mutations such as exon 10 is lower in Japan than in Western countries, and FMF cases in Japan have been reported to more often be adult onset and to more often show atypical clinical symptoms [
9]. Because of the misunderstanding that FMF is rare in Japan, or that there is a higher percentage of earlier onset in Japan, it is possible that the condition’s diagnosis has been delayed [
16].
The onset of FMF in an individual over 40 years of age has been considered rare. A survey of 470 cases showed that approximately 60% of the patients experienced the first attack before 10 years of age, 90% of those experienced the first attack before 20 years of age, and most of the rest of the patients experienced the first attack before 40 years of age [
5]. Although there is no definition to classify later-onset FMF including adult-onset FMF (AOFMF) and late-onset FMF (LOFMF), previous studies defined AOFMF and LOFMF as the onset of FMF over 20 and 40 years of age, respectively [
20,
21], and revealed that a subgroup of patients with AOFMF or LOFMF is characterized by different demographic, clinical, and probably genetic features [
20‐
23]. However, characteristics of later-onset FMF have not yet been fully elucidated in Japan.
In the present study, using data from a nationwide, multicenter, prospective study in Japan, we compared the clinical characteristics and the distribution of MEFV mutations among AOFMF, LOFMF, and YOFMF patients and determined the factors that can distinguish these three groups.
Discussion
Our findings clarified the differences in later-onset FMF including AOFMF and LOFMF. Our data showed that later-onset FMF patients have a shorter diagnostic delay, a lower frequency of family history, a lower frequency of typical cases, a higher frequency of complications of autoimmune or autoinflammatory diseases, and a lower frequency of MEFV mutations in exons 1 and 10. Importantly, our analyses revealed that later-onset FMF patients predominantly present musculoskeletal manifestations, which is independent of overlapping rheumatic diseases and the MEFV mutation in exon 10.
The manifestations of FMF are attributed mainly to the difference in the mutational pattern in the
MEFV gene [
3,
9,
18,
19]. FMF patients with low-penetrance mutations tend to present with milder disease phenotypes and to be diagnosed with atypical FMF [
24‐
26]. In addition, the M694 V mutations in exon 10 mutations, which is high penetrance, are associated with earlier onset and severe phenotypes [
27,
28], suggesting an association between high penetrance and earlier onset. Consistent with these observations, our present analyses demonstrated that the earlier-onset FMF patients had a higher frequency of MEFV exon 10 mutations with high penetrance. Interestingly, our analyses also showed that E84K in exon 1 mutations was significantly more frequent in patients with earlier onset. We confirmed these results by performing the sensitivity analysis excluding the FMF cases with MEFV exon 10 mutations.
The age at disease onset is variable in FMF. As noted in the Introduction, the survey of 470 FMF cases in the 1960s showed that approximately 90% of patients experienced their first attack before 20 years of age, and the onset of FMF at > 40 years of age was rare [
5]. A survey in the 2000s, when FMF had gradually come to be recognized, showed that the proportions of FMF patients whose age at onset was over 20 years and over 40 years were 14% and 1.25%, respectively [
20]. Thus, later-onset FMF has been considered rare worldwide.
In contrast, later-onset FMF is more common in Japan compared to Western countries. Two studies from Japan revealed that the mean ± SD age at onset is 24.2 ± 18.1 years [
9] and 23.7 ± 13.6 years [
17], respectively. The present study showed that age at onset > 20 years and > 40 years occurred in 52% (205/395) and 23% (90/395) of all FMF patients, and our results support the idea that adult-onset FMF is not rare in Japan. We speculate that the genetic characteristics of Japanese FMF patients (i.e., with a lower percentage of
MEFV exon 10 mutations and a higher percentage of
MEFV exon 2 mutations [
9]) may explain the reason for the higher percentage of later-onset Japanese FMF.
A delay in the diagnosis of FMF often occurs, even in endemic areas [
20,
22]. Because of self-limiting attacks that occur in a short period, FMF patients may not see a doctor or may not be referred to a specialized department, making it difficult to diagnose FMF correctly in the early course of the disease. Two studies from endemic areas revealed that the mean delay before diagnosis was 6.0 ± 6.6 years (adult onset) versus 12.1 ± 9.0 years (others) [
20] and was 4.9 ± 5.8 years (late onset) versus 20 ± 13 years (others) [
21], respectively. In line with these observations, our present findings indicate that the age at earlier disease onset caused a delay in diagnosis. This may be attributed to more attention being paid by adults to new manifestations and more effort being made to receive a final diagnosis [
21,
22].
Most studies of childhood FMF demonstrated that FMF affects both sexes equally [
5,
29‐
32]. It was also shown that the proportion of males was not significantly different between the young-onset and adult-onset groups [
20]. However, other studies showed that later-onset FMF is characterized by male predominance [
21,
22]. This is because women with later-onset FMF present a milder disease phenotype, resulting in a lesser likelihood of being diagnosed with FMF [
21]. In the present study, although the proportion of males tended to be higher in the AOFMF group than in the YOFMF group, there was no significant difference between the two groups.
Our previous investigation demonstrated that the presence of
MEFV exon 10 mutations was associated with typical FMF presentation and that typical FMF had a higher frequency of a family history of FMF [
9]. Our present findings showed that earlier-onset FMF patients have significantly higher frequency of a family history as well as
MEFV mutations in exon 10. We considered that high-penetrance mutations such as exon 10 increase the frequency of a family history. We also observed that the YOFMF group had a significantly higher frequency of typical FMF cases, probably because YOFMF patients more frequently have
MEFV mutations in exon 10.
Our study showed that earlier-onset FMF patients predominantly present serositis manifestations including peritonitis and pleuritis, while later-onset FMF patients predominantly present musculoskeletal manifestations including synovitis and myalgia. Conversely, earlier studies showed that arthritis and erysipelas-like erythema are less frequent in adult-onset FMF compared to young-onset FMF [
20,
22], which differs from our observations. However, these earlier studies did not perform sufficient analyses of the genetic differences with age at onset. Similar to our observations, a recent study from a Western country showed that LOFMF patients presented a high frequency of arthritis without significant difference and significantly less frequent chest pain compared to patients with a disease onset before 40 years of age [
33]. It may thus be important to distinguish later-onset FMF from other inflammatory diseases such as crystalline-induced arthropathies and infectious arthritis.
Our multiple logistic regression analysis revealed that the presence of
MEFV exon 10 mutations and earlier onset were significantly associated with serositis during attacks. Although this differs from some previous reports [
20,
22], our analyses also revealed that the absence of
MEFV exon 10 mutations, later onset, and the presence of erysipelas-like erythema were significantly associated with musculoskeletal manifestations. Collectively, our data indicate that the
MEFV mutations in exon 10 with high penetrance are associated with both a high frequency of serositis and a low frequency of musculoskeletal manifestations. Japanese FMF patients not only have a lower percentage of
MEFV exon 10 mutations but also a lower percentage of
MEFV homozygous mutations associated with high penetrance [
9,
17]. In addition, no Japanese FMF patients have the M694 V mutations in exon 10 mutations, which is especially high penetrance [
9,
17]. The discrepancy between our findings and those of previous studies may be explained by the genetic characteristics of Japanese FMF patients, who have a lower percentage of
MEFV mutations with high penetrance, especially in later-onset FMF. In addition, the discrepancy may be associated with racial differences including genetic characteristics other than the
MEFV gene. This study is the first to describe the characteristics of FMF patients with adult onset and late onset in a country (Japan) other than endemic areas, suggesting different characteristics of FMF patients with later onset between endemic areas and other areas. We await the further accumulation of reports from locations other than endemic areas. Interestingly, the presence of erysipelas-like erythema was the strongest factor determining the presence of musculoskeletal manifestations. It was reported that the proportions of arthritis and erysipelas-like erythema are correlated [
20,
22,
34], thus suggesting that these manifestations may develop with similar pathological conditions.
Since colchicine is primarily effective as a prophylactic treatment for FMF attacks, colchicine is recommended in all FMF patients regardless of the frequency and intensity of attacks. Later-onset FMF patients were described as having a milder form of disease and more favorable responses even to low-dose colchicine [
21‐
23]. Most of the FMF patients in the present study had a good response to colchicine and there was no significant difference in secondary amyloidosis suggesting a severe phenotype among the three groups. There is a report showing that FMF patients with high-penetrance M694 V mutation in exon 10 needed higher-dose colchicine to achieve a good response [
28], and there is also a report showing these patients have a significantly lower frequency of complete response to colchicine compared to patients with other MEFV mutations [
35], suggesting that there may be an association between high-penetrance mutations and good response to colchicine. We suspect that Japanese FMF patients have good response to colchicine irrespective of age at onset and that there is no significant difference among the present three patient groups because of the higher frequency of low-penetrance mutations.
There are some study limitations to acknowledge. First, it remains questionable whether the diagnosis of FMF was correct in all of our cases. The diagnosis of FMF should be made based on clinical findings, not on the presence of
MEFV gene mutations [
36]. We also diagnosed FMF based on clinical findings in the present study. However, other hereditary autoinflammatory diseases cannot be completely ruled out. In addition, a good response to colchicine itself is one of the diagnostic criteria [
7], and thus it is possible that patients with a poor response to colchicine were diagnosed as non-FMF.
Second, although we concluded an association with musculoskeletal symptoms and older-onset FMF by a sensitivity analysis after excluding patients with rheumatic disease, a few cases in later-onset FMF may have presented musculoskeletal symptoms due to the presence of subclinical rheumatic diseases. It has been reported that the
MEFV gene mutations can be a risk for rheumatic diseases such as AOSD [
37] and BD [
38], and can modify clinical phenotypes of rheumatic diseases such as RA [
39] and SLE [
40]. In addition, it is generally known that the incidence of autoimmune diseases increases in proportion to age, and it is possible that rheumatic diseases before onset may be included in the adult-onset group or the late-onset group. Although each rheumatologist examined other overlapping rheumatic diseases at the diagnosis of FMF, there was no detailed information available on the profiles of autoantibodies.
Finally, there are no established standard criteria to evaluate the disease activity of FMF and the effectiveness of colchicine, and we were thus unable to evaluate these parameters accurately in the present study. The International Severity Score for FMF (ISSF) was recently recommended as a new criterion for evaluating the disease activity of FMF [
41], and the FMF 50 score [
42] is also recommended as a new criterion for evaluating the effectiveness of treatments such as colchicine and the necessity of intensive treatment. In the future, it is necessary to prospectively compare the disease activity and good response rate to colchicine of patients with young-onset, adult-onset, and late-onset FMF.